PDCD1 and neoplasm: Together, these data support the use of DNT cells as adoptive cellular therapy for NSCLC either alone or in combination with anti-PD-1 and show, for the first time, that anti-PD-1 antibody can increase tumor infiltration of adoptively transferred DNT cells.